The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients

Knuijver, Thomas, ter Heine, Rob, Schellekens, Arnt F. A., Heydari, Paniz, Lucas, Luc, Westra, Sjoerd, Belgers, Maarten, van Oosteren, Toon, Verkes, Robbert Jan, Kramers, Cornelis · 2024 · Journal of Psychopharmacology

AI-extracted · unverified · confirm at source

First human PK/PD study (n=14): CYP2D6 genotype is MAJOR determinant of ibogaine metabolism - clearance varies >10-fold across activity scores. Critical for personalised dosing.

Sample size: 14

Safety data present: QTC

Contraindications: Clinically significant cardiac disease (including ventricular fibrillation, long QT syndrome, syncope history), Baseline QTc >450ms (men) or >470ms (women), Serum potassium <3.5 or >5.0 mmol/L, Severe hepatic or renal dysfunction (eGFR <30), Concurrent QTc-prolonging or CYP2D6-affecting medications (other than methadone) at screening, Major depressive or psychotic symptoms